Combining the PTM- or CTMΔ12EC IFPs with an anti-CD19 CAR resulted in improved tumour control and clearance, as evidenced by bioluminescence imaging, and led to significantly improved survival compared to treatment with CAR only (Fig. 4b, d). The gene discussed is CD19; the disease is neoplasm.